Prostate Cancer

The impact of changing the prevalence of overweight/obesity and physical inactivity in Australia: an estimate of the proportion of potentially avoidable cancers 2013-2037

Globally, 39% of the world's adult population is overweight or obese and 23% is insufficiently active. These percentages are even larger in high-income countries with 58% overweight/obese and 33% insufficiently active.

Theoretical and experimental study of dual-fiber laser ablation for prostate cancer

Single-fiber laser treatment of the prostate has been widely accepted in the clinic due to its minimal invasiveness and high controllability. However, for large tumors, multiple insertions of the laser probe would be needed to achieve full coverage of the tumor, increasing the complexity of the treatment and occasionally resulting in the incomplete killing of tumor cells due to a mismatch between the planned insertion location and the actual probe insertion location.

Obesity is Associated with Upgrading in Prostate Cancers

Prostate cancer (PCa) is the second most common cancer and sixth most common cause of cancer associated death among men in the world. Multiple studies demonstrated the relationship between obesity and PCa in the recent years.

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that the benefit would be greatest in patients with a low metastatic burden.

MicroRNAs as prognostic markers in prostate cancer

Prostate cancer (PCa) is the most commonly diagnosed malignancy in men who are especially over the age of 50 years in the western countries. Currently used therapeutic modalities mostly fail to give positive clinical outcomes and nearly 30% of the PCa patients eventually develop clinical recurrence.

Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone

The aim of this retrospective study is to evaluate the activity and safety of a steroidal switch from prednisone to dexamethasone in patients with advanced, heavily pre-treated, castration-resistant prostate cancer (CRPC) who progressed on abiraterone acetate.

Recent trends in the management of advanced prostate cancer

Advanced prostate cancer includes a wide spectrum of disease ranging from hormone naïve or hormone sensitive to castration resistant, both containing populations of men who have demonstrable metastatic and non-metastatic states.

Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)

Abiraterone acetate plus prednisone is a standard treatment option for mCRPC. The phase II SWITCH trial showed that further prostate-specific antigen (PSA) responses can be obtained in a subset of patients when prednisone was switched to dexamethasone at progression.

Obesity, Risk of Biochemical Recurrence, and PSADT after Radical Prostatectomy: Results from the SEARCH Database

To examine the association between body mass index (BMI) and aggressive biochemical recurrence (BCR) using the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

We identified 4,123 men with complete data treated by radical prostatectomy between 1988 and 2015.

Structure and function of FUS gene in prostate cancer

FUS reduces the proliferator factors such as cyclin D1 and Cdk6, and increases Cdk and p27. Therefore, FUS prevents the growth of prostate cancer cells.

This review tried to summarize data about FUS gene expression in correlation with the degree of prostate cancer.